Gross-to-net accounting in the bio-pharma industry

Are you ready to take your bio-pharma product from clinical trials to commercial success? The journey from research to revenue is complex, and mastering gross-to-net (GTN) accounting is crucial for accurately capturing your product's financial performance. Our comprehensive whitepaper is your essential guide to navigating this critical transition.

What you'll discover

• Strategic planning: Learn how to form a cross-functional GTN planning group that includes key stakeholders from medical affairs, market access, patient support services, finance and more. This collaborative approach ensures all aspects of product launch are meticulously planned and executed.
• Detailed insights: Gain a deep understanding of your product's attributes, patient demographics, and the intricacies of the distribution and reimbursement channels. This knowledge is vital for developing accurate GTN assumptions and forecasting models.
• Practical guidance: From mapping out your distribution channel to understanding third-party logistics (3PL) contracts, our whitepaper provides step-by-step instructions to ensure your GTN function is robust and reliable.
• Financial accuracy: Discover how to track product activity, document GTN methodologies and support financial reporting with clear, actionable steps. This ensures your financial statements reflect the true performance of your product.
• Specialist tips: Benefit from experienced approach to building and maintaining an effective GTN function, including inventory roll-forwards, cost estimation and aligning assumptions with actual activity.

Why download?

This whitepaper is more than just a guide—it's a roadmap to financial success in the bio-pharma industry. Whether you're preparing for a product launch or looking to optimize your current processes, the insights and strategies provided will empower your team to achieve accurate financial reporting and strategic decision-making.

Download Baker Tilly’s whitepaper—Gross-to-net accounting in the bio-pharma industry—now and elevate your approach to the financial complexities of product commercialization.